Dashboard
Manage Tickers

NNVC NANOVIRICIDES, INC.

NYSE nanoviricides.com


$ 1.41 $ -0.06 (-4.11 %)    

Thursday, 13-Nov-2025 12:22:01 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 611.24 $ -6.42 (-1.04 %)
DIA $ 478.45 $ -2.98 (-0.62 %)
SPY $ 675.57 $ -4.85 (-0.71 %)
TLT $ 89.89 $ 0.09 (0.1 %)
GLD $ 386.70 $ -0.58 (-0.15 %)
$ 1.5
$ 1.47
$ 1.40 x 5,867
$ 1.41 x 89
$ 1.40 - $ 1.50
$ 0.94 - $ 2.23
371,264
na
26.15M
$ 0.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 09-29-2025 06-30-2025 10-K
2 05-15-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-Q
4 11-14-2024 09-30-2024 10-Q
5 09-27-2024 06-30-2024 10-K
6 05-15-2024 03-31-2024 10-Q
7 02-14-2024 12-31-2023 10-Q
8 11-14-2023 09-30-2023 10-Q
9 10-13-2023 06-30-2023 10-K
10 05-15-2023 03-31-2023 10-Q
11 02-14-2023 12-31-2022 10-Q
12 11-14-2022 09-30-2022 10-Q
13 10-13-2022 06-30-2022 10-K
14 05-16-2022 03-31-2022 10-Q
15 02-14-2022 12-31-2021 10-Q
16 11-15-2021 09-30-2021 10-Q
17 10-12-2021 06-30-2021 10-K
18 05-14-2021 03-31-2021 10-Q
19 02-16-2021 12-31-2020 10-Q
20 11-16-2020 09-30-2020 10-Q
21 10-13-2020 06-30-2020 10-K
22 06-22-2020 03-31-2020 10-Q
23 02-14-2020 12-31-2019 10-Q
24 11-15-2019 09-30-2019 10-Q
25 08-23-2019 06-30-2019 10-K
26 05-15-2019 03-31-2019 10-Q
27 02-14-2019 12-31-2018 10-Q
28 11-14-2018 09-30-2018 10-Q
29 10-12-2018 06-30-2018 10-K
30 05-21-2018 03-31-2018 10-Q
31 02-20-2018 12-31-2017 10-Q
32 11-14-2017 09-30-2017 10-Q
33 09-28-2017 06-30-2017 10-K
34 05-15-2017 03-31-2017 10-Q
35 02-14-2017 12-31-2016 10-Q
36 11-14-2016 09-30-2016 10-Q
37 09-16-2016 06-30-2016 10-K
38 05-10-2016 03-31-2016 10-Q
39 02-09-2016 12-31-2015 10-Q
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

nanoviricides-prices-3571429-share-securities-purchase-agreement-at-168share-for-gross-proceeds-6m
NanoViricides Prices 3,571,429 Share Secur...
11/11/2025 13:34:13

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
11/10/2025 21:07:39

nanoviricides-receives-drc-approval-to-start-phase-ii-trial-of-nv-387-for-mpox-treatment
NanoViricides Receives DRC Approval To Sta...
11/10/2025 13:35:57

NanoViricides, Inc. (NYSE:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical...

nanoviricides-announces-ceo-dr-anil-diwan-shares-that-companys-lead-drug-nv-387-demonstrated-potent-activity-against-the-measles-virus-in-cell-cultures-and-a-humanized-animal-model-protecting-lung-tissue-and-significantly-extending-survivalfrom-74-days-in-untreated-animals-to-17-days-in-treated-ones
NanoViricides Announces CEO Dr. Anil Diwan...
10/29/2025 12:52:30

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr A...

nanoviricides-says-clinical-lead-drug-nv-387-shows-strong-activity-against-measles-virus-in-cell-culture-studies-as-well-as-in-humanized-animal-model
NanoViricides Says Clinical Lead Drug NV-3...
10/22/2025 12:47:48

NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug ...

nanoviricides-says-clinical-lead-drug-nv-387-shows-strong-activity-against-measles-virus-in-humanized-animal-model-says-nv-387-can-now-be-made-available-for-emergency-use-application-in-measles-patients
NanoViricides Says Clinical Lead Drug NV-3...
10/20/2025 12:47:55

nanoviricides-reports-that-an-analyst-research-report-was-published-on-the-company-that-explains-its-dual-track-clinical-trials-for-nv-387-targeting-mpox-and-respiratory-viruses
NanoViricides Reports That An Analyst Rese...
10/15/2025 12:47:02

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), reports that an analyst research report was published on the Company t...

nanoviricides-q4-eps-013-up-from-019-yoy
Nanoviricides Q4 EPS $(0.13) Up From $(0.1...
09/29/2025 21:55:22

Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.13) per share. This is a 31.58 percent increase over losses of $(0.1...

nanoviricides-intends-to-file-for-orphan-drug-status-for-several-indications-of-nv-387-including-mpox-smallpox-and-measles
NanoViricides Intends To File For Orphan D...
07/23/2025 12:46:46

nanoviricides-highlights-broad-antiviral-effectiveness-of-nv-387-expects-accelerated-development-and-early-revenues-from-mpox-smallpox-and-measles-indications
NanoViricides Highlights Broad Antiviral E...
07/23/2025 12:44:49

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/22/2025 21:06:00

nanoviricides-reports-breakthrough-measles-drug-nv-387-boosts-survival-by-130-in-animal-study
NanoViricides Reports Breakthrough Measles...
07/21/2025 10:32:00

NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the "Company"), and a clinical stage, leading globa...

nanoviricides-announces-that-the-design-of-the-adaptive-clinical-trial-protocol-for-mpox-virus-clade-ia-and-ib-infections-and-disease-is-nearly-complete
Nanoviricides Announces That The Design Of...
07/14/2025 10:32:37

The adaptive clinical trial is designed to provide information on three important aspects in a single, compact clinical trial:s...

nanoviricides-announces-that-it-is-forging-ahead-with-its-measles-drug-development-program
NanoViricides Announces That It Is Forging...
06/04/2025 10:56:35

nanoviricides-says-it-has-been-cleared-to-file-phase-ii-trial-application-for-oral-nv-387-in-mpox-treatment-by-drc-ethics-committee-company-says-it-is-also-readying-to-combat-measles-outbreaks-and-to-tackle-bird-flu
NanoViricides Says It Has Been Cleared To ...
05/16/2025 10:35:19

nanoviricides-q3-gaap-eps-014-up-from-016-yoy
Nanoviricides Q3 GAAP EPS $(0.14) Up From ...
05/15/2025 21:44:24

Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.14) per share. This is a 12.5 percent increase over losses of $(0.16...

nanoviricides-secures-cnes-approval-for-nv-387-phase-ii-clinical-trial-in-democratic-republic-of-congo
NanoViricides Secures CNES Approval For NV...
05/08/2025 10:39:04

NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Et...

nanoviricides-targets-measles-with-broad-spectrum-antiviral-nv-387-as-vaccination-rates-decline
NanoViricides Targets Measles With Broad-S...
04/29/2025 10:48:31

nanoviricides-evaluates-drug-nv-387-for-measles-treatment-targets-virus-spread-with-new-antiviral-approach
NanoViricides Evaluates Drug NV-387 for Me...
04/14/2025 10:34:01

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the d...

nanoviricides-says-business-is-not-affected-by-the-tariff-policies-of-the-us-government
NanoViricides Says Business Is Not Affecte...
03/11/2025 10:34:41

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION